Key terms
About AXNX
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AXNX news
Yesterday
9:38am ET
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
Apr 17
4:00am ET
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
Mar 22
4:02pm ET
Axonics shareholders approve merger with Boston Scientific
Mar 22
6:29am ET
Axonics Modulation Technologies (AXNX) Gets a Hold from Wells Fargo
Mar 21
4:55pm ET
Axonics provides update on inter partes review proceedings
Mar 21
3:00pm ET
Medtronic moves for patent infringement litigation with Axonics to resume
Mar 01
5:00am ET
Axonics Modulation Technologies (AXNX) Receives a Hold from Wells Fargo
Feb 29
4:02pm ET
Axonics responds to ITC action by Medtronic
Feb 29
9:02am ET
Medtronic files ITC action against Axonics
Feb 29
7:17am ET
Axonics Modulation Technologies (AXNX) Gets a Hold from RBC Capital
Feb 28
4:04pm ET
Axonics reports Q4 EPS 13c, consensus 6c
No recent press releases are available for AXNX
AXNX Financials
Key terms
Ad Feedback
AXNX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AXNX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range